Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
XPEV Xpeng Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Postmarket

Last Trade
Delayed
$226.00
0.31 (0.14%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$225.69
Day's Change
-1.35 (-0.59%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
227.89
Day's Low
225.28
Volume
(Average)
Volume:
2,407,477

10-day average volume:
2,435,602
2,407,477

AMGN's position in the Biotechnology industry

Industry PeersAMGNABBVGILDVRTXREGN

Summary

Company ProfileAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are...
Go to ABBV summary
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and...
Go to GILD summary
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing...
Go to VRTX summary
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The...
Go to REGN summary
52-Week Change

VS. INDUSTRY
6.36%
21.60%
-16.43%
-8.71%
-2.13%
Market Cap

VS. INDUSTRY
$131.1B
$191.4B
$78.5B
$54.7B
$49.6B
Beta

VS. INDUSTRY
0.7
0.8
0.4
0.7
0.2
Dividend Yield

VS. INDUSTRY
3.10%
4.80%
4.55%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
18.44x
40.01x
1,096.56x
20.42x
15.09x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$25.4B
$45.8B
$24.7B
$6.2B
$8.5B
Profit Margin

VS. INDUSTRY
28.57%
10.09%
0.36%
43.70%
41.35%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
6.33%
-2.82%
-61.76%
--
40.78%
Revenue Growth (TTM)

VS. INDUSTRY
8.83%
37.69%
9.98%
49.07%
23.80%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.